Eikon Therapeutics, Inc. Common Stock (EIKN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has a cash flow conversion efficiency ratio of 0.047x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.72 Million) by net assets ($-879.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eikon Therapeutics, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Eikon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Eikon Therapeutics, Inc. Common Stock cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Eikon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zero One Technology Co Ltd
TW:3029
|
-0.013x |
|
People & Technology Inc
KQ:137400
|
0.023x |
|
Olympic Steel Inc
NASDAQ:ZEUS
|
-0.009x |
|
Hunan Huasheng Co Ltd
SHG:600156
|
0.086x |
|
Guangdong Piano Customized Furniture Co Ltd
SHE:002853
|
0.016x |
|
Kenda Rubber Industrial Co Ltd
TW:2106
|
-0.003x |
|
National Petroleum Co Ltd
TW:9937
|
0.039x |
|
Shanghai Dragon Corp
SHG:600630
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Eikon Therapeutics, Inc. Common Stock from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see Eikon Therapeutics, Inc. Common Stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-879.03 Million | $-188.52 Million | 0.214x | -9.01% |
| 2024-12-31 | $-571.93 Million | $-134.80 Million | 0.236x | -57.84% |
| 2023-12-31 | $-341.37 Million | $-190.85 Million | 0.559x | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more